# A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906

> **NCT05296733** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 82 (actual)

## Conditions studied

- Healthy
- Liver Diseases
- Obesity

## Interventions

- **DRUG:** BI 456906

## Key facts

- **NCT ID:** NCT05296733
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-27
- **Primary completion:** 2023-12-29
- **Final completion:** 2023-12-29
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2024-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05296733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05296733, "A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05296733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*